Sanofi pays $11.6bn for biotech group Bioverativ
French pharma giant Sanofi has agreed an $11.6bn deal for Bioverativ, a biotech company specialising in haemophilia therapies. The deal provides Sanofi with a platform for growth in this and other rare blood disorders, particularly through the advance of Fitusiran. Fitusiran is a factor replacement therapy to which Sanofi has global development and commercialisation rights that is expected to be the standard of care in haemophilia for years to come. Worth around $10bn a year and with 181,000 people affected worldwide, haemophilia is the largest market for rare diseases. In 2016, Bioverativ raised $847m in sales and $41m in royalties.